Compare AIRG & QTTB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AIRG | QTTB |
|---|---|---|
| Founded | 1995 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Radio And Television Broadcasting And Communications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 47.4M | 44.3M |
| IPO Year | 2016 | 2018 |
| Metric | AIRG | QTTB |
|---|---|---|
| Price | $5.33 | $7.25 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 1 |
| Target Price | $6.25 | ★ $13.00 |
| AVG Volume (30 Days) | 70.0K | ★ 270.6K |
| Earning Date | 05-06-2026 | 03-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 31.65 | ★ 136.78 |
| EPS | N/A | ★ 2.42 |
| Revenue | $51,779,000.00 | ★ $53,737,000.00 |
| Revenue This Year | $10.31 | N/A |
| Revenue Next Year | $20.71 | N/A |
| P/E Ratio | ★ N/A | $2.95 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.00 | $1.38 |
| 52 Week High | $5.85 | $7.85 |
| Indicator | AIRG | QTTB |
|---|---|---|
| Relative Strength Index (RSI) | 67.59 | 68.43 |
| Support Level | $3.95 | $3.49 |
| Resistance Level | $5.74 | $7.80 |
| Average True Range (ATR) | 0.31 | 0.90 |
| MACD | 0.17 | 0.06 |
| Stochastic Oscillator | 87.70 | 70.83 |
Airgain Inc is engaged in providing antenna technologies. These technologies can be used to enable performance wireless networking across devices and markets which include connected homes, enterprises, automotive, and the Internet of Things. It also provides solutions to complex radio frequency, engineering challenges, and improving wireless service that require higher throughput, broad coverage footprint, and carrier-grade quality. Geographically, it derives maximum revenue from North America and also has a presence in China and the Rest of the World. The company products include Antenna Plus: Fleet, M2M, IoT Antennas, Carrier-Class Antenna, Embedded Antennas, and External Dipole Antennas.
Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to effectively and safely restore healthy immune balance in patients with autoimmune & inflammatory diseases driven by pathological immune dysfunction. Q32 is advancing antibody-based therapeutic candidates designed to target two central pathways of adaptive & innate immunity. The adaptive immune system is largely composed of T- & B-cell mediated cellular & antibody responses, while the innate immune system is the body's first line of defense employing leukocytes that are responsible for clearing pathogens and cellular debris and modulating T- & B-cell function.